SUPPRELIN® LA - Designed for Control

SUPPRELIN LA is the first and only 12-month implant to treat central precocious puberty1

The once-yearly implant offers you the confidence to:

  • Minimize the potential for interrupted suppression with continuous therapy1,2
  • Start and stop the delivery of medication with a minor surgical procedure1,2
  • Schedule monitoring appointments around your, and your patients', schedules
  • Help your patients receive continuous therapy for an entire year1

Both healthcare providers and patients choose the control of SUPPRELIN LA

  • After 1 year in a phase 3 study, 97% of patients (31/32) opted to receive a second SUPPRELIN LA implant2
  • Over 7,000 implants...and counting

To help patients locate healthcare professionals who treat Central Precocious Puberty (CPP) in their area, we are creating a searchable database of physicians. To take advantage of this opportunity, please go to our doctor finder sign-up page.

References:
1. SUPPRELIN® LA [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc; 2011.
2. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704

Next: Diagnosing Central Precocious Puberty

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA is contraindicated in women who are or may become pregnant, and in patients who are hypersensitive to GnRH or GnRH agonist analogs. Safety and effectiveness in pediatric patients under the age of 2 years has not been established.

  • SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease.

  • Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (this implant is not radiopaque).

  • Rare events of spontaneous extrusion have been observed in clinical trials.

  • LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should also be assessed.

  • In clinical trials, the most common adverse reactions involved the implant site and included bruising, pain, soreness, erythema and swelling.

Please see the accompanying full Prescribing Information.